Who Paid My Doc
Aditya Bharadwaj
Interventional Cardiology Loma Linda, CA Medical Doctor
NPI 1871729822 CMS profile 1380107
11234 Anderson St Spc 1617, Loma Linda, CA 92354
General payments
$380,374
Research payments
$341
Ownership & investment interest
$0
Research they led as principal investigator
$10,272
Through program year 2025, Aditya Bharadwaj of Loma Linda, CA is reported in the CMS Open Payments database as having received $380,374 across 324 general payments and $341 in research payments paid to them. Separately, studies naming them as principal investigator received $10,272 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $14,642 | 18 | |
| 2024 | General | $58,011 | 46 | |
| 2023 | General | $111,384 | 73 | |
| 2023 | Research | $341 | 4 | |
| 2022 | General | $80,890 | 66 | |
| 2021 | General | $70,807 | 47 | |
| 2020 | General | $39,951 | 45 | |
| 2019 | General | $4,687 | 29 |
Beside peers
- Aditya Bharadwaj
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Aditya Bharadwaj were reported at $14,642. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Aditya Bharadwaj | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,687 | $1,097 | $329–$3,048 | $163 |
| 2020 | $39,951 | $473 | $161–$1,480 | $114 |
| 2021 | $70,807 | $677 | $233–$1,827 | $132 |
| 2022 | $80,890 | $978 | $333–$2,724 | $149 |
| 2023 | $111,384 | $1,136 | $382–$2,986 | $160 |
| 2024 | $58,011 | $1,181 | $395–$3,326 | $164 |
| 2025 | $14,642 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 23 drugsPart D claims
920
Drug cost
$188,917
Branded share of claims
32.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | Brand | 42 | $56,259 | |
| Eliquis Apixaban | Brand | 55 | $47,972 | |
| Farxiga Dapagliflozin Propanediol | Brand | 31 | $32,349 | |
| Brilinta Ticagrelor | Brand | 35 | $24,282 | |
| Xarelto Rivaroxaban | Brand | 18 | $19,206 | |
| Ranolazine Er Ranolazine | Brand | 18 | $1,809 | |
| Metoprolol Succinate | Generic | 89 | $941 | |
| Atorvastatin Calcium | Generic | 78 | $887 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 75 | $845 | |
| Carvedilol | Generic | 72 | $630 |
The 10 drugs with the highest cost, of 23 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 41 billing codesPaid by Medicare
$79,875
Medicare patients
357
Services billed
677
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 53% | |
| Arthritis | 53% | |
| Ischemic heart disease | 52% | |
| Heart failure | 44% | |
| Chronic kidney disease | 38% | |
| Atrial fibrillation | 32% | |
| COPD | 22% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
328 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in California
Matthew Price
Interventional Cardiology · La Jolla, CA
Frederick St Goar
Interventional Cardiology · Mountain View, CA
Saibal Kar
Interventional Cardiology · Thousand Oaks, CA
Rahul Sharma
Interventional Cardiology · Stanford, CA
Puneet Khanna
Interventional Cardiology · Rancho Mirage, CA
Dennis Sheehan
Interventional Cardiology · Redwood City, CA
Related records
Interventional Cardiology in California
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.